Dermata Therapeutics (DRMA) stock

Worth $2.9MShares as of Aug 10

$0.71

-7.21%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score DRMA. It is too small and priced too low for a fair Quality Score.

Healthcare · Biotech

Cash$4.4M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into the first quarter of 2027”

Follow DRMA's news. Pro members can get an alert when Dermata Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when DRMA files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$4.4M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into the first quarter of 2027”

What's next for DRMA, and how long its cash lasts

Cash runway Jun 30 balance sheet

About 2 quarters

$4.4M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the first quarter of 2027” (8-K, Nov 10).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Nov 24, 2025)
At-the-market share sales program (424B5, filed Jan 27, 2026)

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

Director Kathleen D. Scott sold 11 shares on Jun 16. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

Get an alert when Gerald Proehl buys or sells

For Pro members: every trade, and Gerald Proehl’s 10 filings and quotes.

Get an alert when DRMA files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

DRMA's latest filings

Quarterly report10-Q, filed Nov 10
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 20268-K, filed Nov 10
Prospectus for a sale of securities424B3, filed Oct 21

28 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why DRMA isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. DRMA is worth about $2.9M and trades at $0.71. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.